In 2023, Spain led European anxiolytic medicine sales with 107.7 million euros, demonstrating a moderate growth of 1.21% from the previous year. Belgium followed with 63.1 million euros, showing a slight decline of 1.1%. Portugal and Greece saw reductions of 0.85% and 7.03%. Slovakia and Italy showed significant growth, with increases of 8.84% and 8.45%. Finland, Slovenia, and Estonia showed marginal increases of 1.52%, 1.44%, and 4.24%, respectively. The five-year CAGR indicates a stable demand for Spain, Slovakia, and Italy, with potential growth opportunities.
Future trends to watch include potential market expansion in Slovakia and Italy due to their recent growth patterns. The forecasted data suggests shifts in consumer behavior and potential regulatory impacts, especially in countries with declining sales like Greece and Belgium.
Top countries in Anxiolytic Medicine Sales by Country
| # | 9 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Spain | 107.7 | 2023 | -0.28% | +1.21% | View data |
| 2 | 2 Belgium | 63.1 | 2023 | -0.47% | -1.1% | View data |
| 3 | 3 Portugal | 48.4 | 2023 | -0.21% | -0.85% | View data |
| 4 | 4 Greece | 15.7 | 2023 | 0% | -7.03% | View data |
| 5 | 5 Slovakia | 11.3 | 2023 | +5.61% | +8.84% | View data |
| 6 | 6 Finland | 6.9 | 2023 | -1.43% | +1.52% | View data |
| 7 | 7 Italy | 4.8 | 2023 | +6.67% | +8.45% | View data |
| 8 | 8 Slovenia | 2.9 | 2023 | 0% | +1.44% | View data |
| 9 | 9 Estonia | 1.6 | 2023 | 0% | +4.24% | View data |
